MAQS advised QuiaPEG in connection with directed issues of approx. SEK 16 million

MAQS has advised QuiaPEG Pharmaceuticals Holding AB (publ) in connection with two directed issue of shares and warrants to several Swedish and international investors and a directed issue of convertibles directed towards to certain creditors of the company.

QuiaPEG’s business strategy is to build a pipeline of drug development projects using its releasable pegylation technology that will be offered for out-licensing to potential development partners. QuiaPEGs shares are listed on Nasdaq First North Growth Market. The issues were announced by QuiaPEG on 31 August and 14 September 2021.

For further information about the issues and QuiaPEG, please refer to the company’s website, www.quiapeg.com